Fig. 5: AFP percentage change from baseline by cycle. | British Journal of Cancer

Fig. 5: AFP percentage change from baseline by cycle.

From: Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab

Fig. 5

Medians of AFP percentage changes from baseline were plotted every three cycles for the pooled population of patients with AFP ≥ 400 ng/ml in the REACH-2 and REACH studies by treatment arm: a for all patients, b for patients with the best overall response of CR/PR, c for patients with the best overall response of CR/PR/SD and d) for patients with the best overall response of PD. AFP alpha-fetoprotein, CR complete response, ITT intent to treat, PBO placebo, PD progressive disease, PR partial response, RAM ramucirumab, SD stable disease.

Back to article page